Stimulant use disorders in people with psychosis: A meta-analysis of rate and factors affecting variation

Australian and New Zealand Journal of Psychiatry

Volumn 49, Issue 2, 2015, Pages 106-117

  Sara, Grant E ^a,b,c   Large, Matthew M ^d,e   Matheson, Sandra L ^f   Burgess, Philip M ^c   Malhi, Gin S ^b,g   Whiteford, Harvey A ^c   Hall, Wayne D ^c  

^a New South Wales Government   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d PRINCE OF WALES HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

affective psychosis; amphetamine; cocaine; ecstasy; schizophrenia; systematic review

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; METHAMPHETAMINE;

AFFECTIVE PSYCHOSIS; AUSTRALIA; CANNABIS ADDICTION; COCAINE DEPENDENCE; DRUG ABUSE; HUMAN; META ANALYSIS; METHAMPHETAMINE DEPENDENCE; PREVALENCE; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE; UNITED STATES; COMORBIDITY; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS;

CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; HUMANS; PSYCHOTIC DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 84921374604     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414561526     Document Type: Review

References (56)

1. Adlaf E, Begin P, Sawka E Prevalance of use and related harms - Detailed report. Ottowa: Canadian Centre on Substance Abuse ; 2005 :
2. Agar M, Reisinger HS. Ecstasy: commodity or disease?. Journal of Psychoactive Drugs. 2004 ; 36: 253-264
3. A national approach to mental health - from crisis to community. First report. Canberra: Commonwealth of Australia ; 2006 :
4. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophrenia Research. 2005 ; 77: 43-58
5. Bedard AM, Maheux J, Levesque D, et al. Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia. Schizophrenia Bulletin. 2013 ; 39: 692-702
6. Blum K, Cull JG, Braverman ER, et al. Reward Deficiency Syndrome. American Scientist. 1996 ; 84: 132-145
7. Bramness JG, Gundersen OH, Guterstam J, et al. Amphetamine-induced psychosis - A separate diagnostic entity or primary psychosis triggered in the vulnerable?. BMC Psychiatry. 2012 ; 12: 221
8. Chen CK, Lin SK, Sham PC, et al. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychological Medicine. 2003 ; 33: 1407-1414
9. Compton M, Weiss PS, West JC, et al. The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems. Social Psychiatry and Psychiatric Epidemiology. 2005 ; 40: 939-946
10. Crebbin K, Mitford E, Paxton R, et al. First-episode drug-induced psychosis: a medium term follow up study reveals a high-risk group. Social Psychiatry and Psychiatric Epidemiology. 2009 ; 44: 710-715
11. Curran C, Byrappa N, McBride A. Stimulant psychosis: a systematic review. British Journal of Psychiatry. 2004 ; 185: 196-204
12. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012 ; 379: 55-70
13. Degenhardt L, Baxter AJ, Lee YY, et al. The global epidemiology and burden of psychostimulant dependence: findings from the Global Burden of Disease Study 2010. Drug and Alcohol Dependence. 2014 ; 137: 36-47
14. Degenhardt L, Chiu WT, Conway K, et al. Does the 'gateway' matter? Associations between the order of drug use initiation and the development of drug dependence in the National Comorbidity Study Replication. Psychological Medicine. 2009 ; 39: 157-167
15. Degenhardt L, Coffey C, Carlin JB, et al. Who are the new amphetamine users? A 10-year prospective study of young Australians. Addiction. 2007a ; 102: 1269-1279
16. Degenhardt L, Coffey C, Moran P, et al. The predictors and consequences of adolescent amphetamine use: findings from the Victoria Adolescent Health Cohort Study. Addiction. 2007b ; 102: 1076-1084
17. Degenhardt L, Dierker L, Chiu WT, et al. Evaluating the drug use 'gateway' theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug and Alcohol Dependence. 2010 ; 108: 84-97
18. Degenhardt L, Roxburgh A, Black E, et al. The epidemiology of methamphetamine use and harm in Australia. Drug and Alcohol Review. 2008 ; 27: 243-252
19. Durell TM, Kroutil LA, Crits-Christoph P, et al. Prevalence of nonmedical methamphetamine use in the United States. Substance Abuse Treatment, Prevention, and Policy. 2008 ; 3: 19
20. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000 ; 56: 455-463
21. Gearon JS, Bellack AS. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients. Schizophrenia Research. 2000 ; 43: 65-70
22. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harvard Review of Psychiatry. 1999 ; 6: 287-296
23. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry. 1996 ; 40: 1155-1163
24. Hermens DF, Lubman DI, Ward PB, et al. Amphetamine psychosis: a model for studying the onset and course of psychosis. Medical Journal of Australia. 2009 ; 190: S22-25
25. Hides L, Dawe S, Kavanagh D, et al. Psychotic symptom and cannabis relapse in recent-onset psychosis - Prospective study. British Journal of Psychiatry. 2006 ; 189: 137-143
26. Kittirattanapaiboon P, Mahatnirunkul S, Booncharoen H, et al. Long-term outcomes in methamphetamine psychosis patients after first hospitalisation. Drug and Alcohol Review. 2010 ; 29: 456-461
27. McKetin R, Lubman DI, Baker AL, et al. Dose-related psychotic symptoms in chronic methamphetamine users: Evidence from a prospective longitudinal study. JAMA Psychiatry. 2013 ; 70: 319-324
28. McKetin R, McLaren J, Lubman DI, et al. The prevalence of psychotic symptoms among methamphetamine users. Addiction. 2006 ; 101: 1473-1478
29. McLellan AT, Druley KA. Non-random relation between drugs of abuse and psychiatric diagnosis. Journal of Psychiatric Research. 1977 ; 13: 179-184
30. Martins SS, Gorelick DA. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug and Alcohol Dependence. 2011 ; 119: 28-36
31. Mathias S, Lubman DI, Hides L. Substance-induced psychosis: a diagnostic conundrum. Journal of Clinical Psychiatry. 2008 ; 69: 358-367
32. Mauri MC, Volonteri LS, De Gaspari IF, et al. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clinical Practice and Epidemiology in Mental Health. 2006 ; 2: 4
33. Miller FT, Tanenbaum JH. Drug abuse in schizophrenia. Hospital and Community Psychiatry. 1989 ; 40: 847-849
34. Mueser KT, Drake RE, Wallach MA. Dual diagnosis: A review of etiological theories. Addictive Behaviors. 1998 ; 23: 717-734
35. Mueser KT, Yarnold PR, Bellack AS. Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder. Acta Psychiatrica Scandinavica. 1992 ; 85: 48-55
36. Paparelli A, Di Forti M, Morrison PD, et al. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Frontiers in Behavioural Neuroscience. 2011 ; 5: 1-9
37. Petersen L, Jeppesen P, Thorup A, et al. Substance abuse and first-episode schizophrenia-spectrum disorders. The Danish OPUS trial. Early Intervention in Psychiatry. 2007 ; 1: 88-96
38. Power BD, Stefanis NC, Dragovic M, et al. Age at initiation of amphetamine use and age at onset of psychosis: The Australian Survey of High Impact Psychosis. Schizophrenia Research. 2014 ; 152: 300-302
39. Rabinowitz J, Bromet EJ, Lavelle J, et al. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychological Medicine. 1998 ; 28: 1411-1419
40. Ruiz-Veguilla M, Gurpegui M, Barrigon ML, et al. Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use. Schizophrenia Research. 2009 ; 107: 158-164
41. Sara G. Cannabis, stimulants and psychosis. Commentary on Gururajan et al. (2012): drugs of abuse and increased risk of psychosis development. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 1196-1197
42. Sara G, Burgess P, Harris MG, et al. Stimulant use and stimulant disorders in Australia: Findings from the National Survey of Mental Health and Wellbeing. Medical Journal of Australia. 2011a ; 195: 607-610
43. Sara G, Burgess P, Harris MG, et al. Stimulant disorders: Characteristics and correlates in an Australian population sample. Australian and New Zealand Journal of Psychiatry. 2012 ; 46: 1165-1172
44. Sara G, Burgess P, Malhi G, et al. Amphetamine availability and admissions for psychosis in New South Wales, 2001-2009. Australian and New Zealand Journal of Psychiatry. 2011b ; 45: 317-324
45. Sara G, Burgess P, Malhi G, et al. Differences in associations between cannabis and stimulant disorders in first admission psychosis. Schizophrenia Research. 2013 ; 147: 216-222
46. Sara G, Burgess P, Malhi G, et al. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis. Journal of Clinical Psychiatry. 2014a ; 75: 349-356
47. Sara G, Burgess PM, Malhi G, et al. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample. Australian and New Zealand Journal of Psychiatry. 2014b ; 48: 1036-1047
48. Sevy S, Kay SR, Opler LA, et al. Significance of cocaine history in schizophrenia. Journal of Nervous and Mental Disease. 1990 ; 178: 642-648
49. Strakowski SM, McElroy SL, Keck PE, et al. The effects of antecedent substance abuse on the development of first-episode psychotic mania. Journal of Psychiatric Research. 1996 ; 30: 59-68
50. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in Epidemiology: A proposal for reporting. JAMA. 2000 ; 283: 2008-2012
51. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings. Rockville, MD: Office of Applied Studies ; 2010 :
52. Amphetamines and Ecstasy, 2011 Global ATS Assessment. Vienna: United Nations ; 2011 :
53. Van Os J. The many continua of psychosis. JAMA Psychiatry. 2014 ; 71: 985-986
54. Wade D, Harrigan S, Edwards J, et al. Patterns and predictors of substance use disorders and daily tobacco use in first-episode psychosis. Australian and New Zealand Journal of Psychiatry. 2005 ; 39: 892-898
55. Wilkins C, Sweetsur P, Casswell S. Recent population trends in amphetamine use in New Zealand: comparisons of findings from national household drug surveying in 1998, 2001, and 2003. New Zealand Medical Journal. 2006 ; 119: U2285
56. Yui K, Ikemoto S, Ishiguro T, et al. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Annals of the New York Academy of Sciences. 2000 ; 914: 1-12